Solta Medical's Clear + Brilliant(TM) Resurfacing Device Demonstrates Significant Reduction of Pore Count and Pore Size
April 16 2012 - 10:07AM
PR Newswire (Canada)
Fractional Laser System Improves Skin Texture and Overall
Appearance HAYWARD, Calif., April 19, 2012 /CNW/ - Solta Medical,
Inc. , the pioneer in fractional resurfacing and a global market
leader in aesthetic treatments, today announced the results of a
first-of-its-kind, IRB-approved clinical study that evaluated the
use of its novel 1440nm fractional laser to assess the effect of
this treatment on the appearance of pores, skin texture and overall
appearance of skin. The study utilized Solta's newest fractional
resurfacing platform, the Clear + Brilliant™ Laser System, which is
used by clinicians worldwide to help patients prevent the initial
signs of photo-aging, maintain the look and feel of their youthful
appearance, and improve the texture and tone of aging and
sun-damaged skin. The complete research findings will be presented
at the 32nd American Society for Laser Medicine and Surgery (ASLMS)
Annual Conference in Kissimmee, Fla. on April 18 through April 22,
2012. The clinical study is the first to objectively measure the
effects of a fractional device on facial pores. It included 20
patients (Fitzpatrick I-IV) who received six treatments spaced two
weeks apart. Each patient received a full-face treatment consisting
of eight passes at the highest tolerable energy level. A
photographic assessment of facial pores using the VISIA-CR Imaging
system was performed before treatment at each visit and subjective
measurements were recorded by both the subject and investigator
regarding pore appearance, appearance of skin texture, and overall
skin appearance. After a series of six treatments, there was a
significant reduction in pore score (p0.002) and investigators and
subjects noted moderate-to-marked improvement in pore appearance,
including pore count and size. Ninety-five percent of all patients
treated reported visible improvement in pore appearance, with 60
percent reporting at least moderate-marked improvement. In
addition, 100 percent of patients reported improvement in skin
texture and overall appearance, with 90 percent reporting at least
moderate-marked improvement. The treatment was well tolerated with
some mild-moderate erythema and less-than-mild edema and there were
no long term side effects and no serious adverse effects reported.
"This research is exciting since pore size has never been
systematically studied before and it is such an area of concern for
patients," said clinical investigator Jeffrey S. Dover, M.D.,
Associate Clinical Professor of Dermatology, at Yale University
School of Medicine, and co-founder of SkinCare Physicians, in
Chestnut Hill, Mass. "The results demonstrate that Clear +
Brilliant can improve not only the tone and texture of the skin,
but also can significantly reduce both pore count and pore size in
all skin types." Dr. Dover and Dr. Nazanin Saedi will be presenting
these findings at ASLMS on Saturday, April 21st during the
Cutaneous Laser Surgery Session from 3:45-3:51 p.m. in Florida Hall
D (reference page 80). "Solta Medical is pleased with the results
of this study and the potential Clear + Brilliant has for
addressing an important aesthetic patient need," said Stephen J.
Fanning, Chairman of the Board, president and CEO of Solta Medical,
Inc. "Support for this study is part of Solta's ongoing commitment
to the aesthetic medical community to provide clinicians with the
data they need to make informed choices on behalf of their
patients." For more information on Solta Medical, please visit
www.Solta.com and Solta Medical (booth # 708). ABOUT SOLTA MEDICAL,
INC. Solta Medical, Inc. is a global leader in the medical
aesthetics market providing innovative, safe, and effective
solutions for patients that enhance and expand the practice of
medical aesthetics for physicians. The company offers six aesthetic
energy devices to address a range of issues, including skin
resurfacing and rejuvenation with Fraxel® and Clear + Brilliant™,
body contouring and skin tightening with Liposonix® and Thermage®
and acne reduction with Isolaz® and CLARO™. As the innovator and
leader in fractional laser technology, Fraxel delivers minimally
invasive clinical solutions to resurface aging and sun damaged
skin. Using similar fractional laser technology, Clear + Brilliant
is a unique, cost-effective treatment to prevent and improve the
early signs of photoaging. For body contouring, Liposonix is a
non-surgical treatment to reduce waist circumference with advanced
high-intensity focused ultrasound (HIFU) technology to permanently
destroy targeted fat beneath the skin. Thermage is an innovative,
non-invasive radiofrequency procedure for tightening and contouring
skin. Isolaz was the first laser or light based system indicated
for the treatment of inflammatory acne, comedonal acne, pustular
acne, and mild-to-moderate inflammatory acne. CLARO is a personal
care acne system that is the first FDA cleared over-the-counter IPL
device that uses a powerful combination of both heat and light to
clear skin quickly and naturally. More than two million procedures
have been performed with Solta Medical's portfolio of products
around the world. For more information about Solta Medical, call
1-877-782-2286 or log on to www.Solta.com. © 2012 Solta Medical,
Inc. All rights reserved. Thermage, Fraxel, Isolaz, Clear +
Brilliant, CLARO, Liposonix and Solta Medical are trademarks or
registered trademarks of Solta Medical, Inc. or its subsidiaries.
SOURCE Solta Medical, Inc. Solta Medical, Inc. CONTACT: Jennifer
Hacker of Cohn & Wolfe,
+1-404-260-3509,jennifer.hacker@cohnwolfe.comhttp://www.solta.com
Copyright
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jul 2023 to Jul 2024